Taking people in GermanyPhase 1
Long-term safety of GD2IL18CART cell therapy in people with certain cancers
Follows people with advanced breast cancer, neuroblastoma, osteosarcoma or Ewing sarcoma after treatment.
Key facts
- Who runs it
- Universitaet Muenster
- Where
- Erlangen, Essen, Muenster, and Tuebingen, GermanySee the 4 sites
- Trial code
- Registry title
- Long-term follow-up of patients treated with GD2IL18CART
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 20 people, planned
- Started
- 6 Oct 2025
- Expected to end
- 31 May 2041
- Type of study
- Interventional
- Record updated
- 23 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who were treated with GD2IL18CART in an earlier (primary) trial. It follows them over time to check long-term safety.
- Sex
- All sexes can join.
- Earlier treatment
- People must have been treated with GD2IL18CART in the primary trial before joining.
Main reasons for not taking part
- No exclusion criteria are defined for this trial.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patient underwent treatment with GD2IL18CART in the primary trial prior to enrollment into long-term follow-up
- Patient and/or caregivers have provided informed consent at any time prior to the first trial-specific assessment
Who cannot take part
- No exclusion criteria are defined for this long-term follow-up trial
Where in Germany
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
- Universitaet MuensterMuenster, GermanyTaking people
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyTaking people
About the trial
What the trial wants to find out
To evaluate long-term safety after treatment with GD2IL18CART
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Long-term follow-up of patients treated with GD2IL18CART
- Plain-language title
- Long-term safety of GD2IL18CART cell therapy in people with certain cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 23 September 2026